The company is now a leaner entity with a retained SEED stake and a data-rights-based bet on DUBLIN-4. The ATM overhang and Nasdaq deficiency are the primary near-term risks. Watch for DUBLIN-4 enrollment updates and any Nasdaq compliance plan filing.
Price Chart
Executive Summary
BeyondSpring completed the sale of its Chinese subsidiary (Bulin) to Biolin Investment Limited on September 30, 2026, receiving no cash consideration. Instead, the company obtained an exclusive, perpetual, royalty-free license to clinical data from the China portion of the DUBLIN-4 Phase 3 trial of Plinabulin + docetaxel, plus a clawback right if enrollment targets are missed. The deconsolidation removes ~$47.6M in assets and ~$47.2M in liabilities, leaving a pro-forma entity with $1.5M cash, a ~$18.8M retained stake in SEED Therapeutics, and a $53.7M preliminary pro-forma gain on disposition. The concurrent ATM offering of up to 9.2M shares and a Nasdaq minimum bid price deficiency notice add dilution and delisting risk.
Key Facts
- Sale closed September 30, 2026 — no cash consideration received; consideration is a data license and trial funding commitment
- Pro-forma cash drops from $2.7M to $1.5M; total assets fall from $14.6M to $21.1M (including $18.8M SEED stake)
- Pro-forma net loss from continuing operations for H1 2026 is $(3.7M), or $(0.09) per share
- Preliminary pro-forma gain on disposition of $53.7M recognized in equity (not in continuing ops)
- Company retains ~29% voting power in SEED Therapeutics post-sale
- Clawback provision: if DUBLIN-4 China enrollment target not met in 3 years, investor returns equity interests — up to 100% if shortfall ≥90%
- Concurrent ATM offering of up to 9.2M shares and Nasdaq minimum bid price deficiency notice (from cross-filing context)
Financial Impact
Pro-forma cash reduced by $1.2M to $1.5M; total liabilities reduced from $50.6M to $3.8M; $29.5M deferred revenue eliminated; $53.7M preliminary gain on disposition recorded in equity
Risk Factors
- Nasdaq minimum bid price deficiency — potential delisting if not cured
- ATM equity offering of up to 9.2M shares creates dilution overhang for a pre-revenue biotech
- No cash consideration received — future value depends entirely on DUBLIN-4 data and SEED stake
- Clawback risk: if enrollment targets missed, data rights may be partially or fully reversed
- Pro-forma net loss from continuing ops of $(3.7M) in H1 2026 with only $1.5M cash on hand
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-006465 |
| Document: f8k_100626.htm | 0001171843-26-006465 |
| Document: 0001171843-26-006465-index-headers.html | 0001171843-26-006465 |
| Document: 0001171843-26-006465-index.html | 0001171843-26-006465 |
| Document: 0001171843-26-006465.txt | 0001171843-26-006465 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 8-K | $0.6450 $0.5870 | ▼ −8.99% | ▼ −8.01% | $0.4620 (−28.37%) |
Oct 2, 2026 25d ago | 8-K | $0.7860 $0.6155 | ▲ +21.69% | ▲ +22.11% | $0.4620 (+41.22%) |
Sep 29, 2026 28d ago | 8-K | $0.7733 $0.6923 | ▼ −10.47% | ▼ −12.42% | $0.4620 (−40.26%) |
Sep 29, 2026 28d ago | 424B5 | $0.7733 $0.6923 | ▲ +10.47% | ▲ +12.42% | $0.4620 (+40.26%) |
Sep 18, 2026 5w ago | 8-K | $0.7400 $1.12 | ▼ −51.35% | ▼ −52.37% | $0.4620 (+37.57%) |
Sep 3, 2026 7w ago | DEFA14A | $0.6181 $0.7600 | ▲ +22.96% | ▲ +24.17% | $0.4620 (−25.25%) |
Aug 14, 2026 10w ago | 8-K | $0.7115 $0.7092 | ▼ −0.32% | ▲ +0.87% | $0.4620 (−35.07%) |
Aug 14, 2026 10w ago | Press Release | $0.7115 $0.7092 | ▼ −0.32% | ▲ +0.87% | $0.4620 (−35.07%) |
Jun 4, 2026 20w ago | 8-K | $1.71 $1.65 | ▼ −3.51% | ▼ −0.96% | $0.4620 (−72.98%) |
Jun 2, 2026 21w ago | Press Release | $1.70 $1.72 | ▲ +1.18% | ▲ +4.14% | $0.4620 (−72.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers